Feasibility of manufacture of chimeric antigen receptor-regulatory T cells from patients with end-stage renal disease

Table 1 Summary of procedure-emergent adverse events

MedDRA preferred term	Number of patients with events	Number of events
MedDRA preferred term	Number of patients with events	CTCAE grade 1	CTCAE grade 2	Total
Haemoglobin decreased	3	2	1	3
Asthenia	2	1	1	2
Leukopenia	2	2	0	2
Anaemia	1	0	1	1
Paraesthesia	1	1	0	1
Nausea	1	1	0	1
Cough	1	1	0	1
Hypertension	1	0	1	1
Total	4	8	4	12

There were no adverse events of CTCAE grade 3 or higher.
CTCAE Common Terminology Criteria for Adverse Events, MedDRA Medical Dictionary for Regulatory Activities

ISSN: 2396-832X